Toxic shock syndrome secondary prevention

Jump to navigation Jump to search

Toxic shock syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Toxic Shock Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Toxic shock syndrome secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Toxic shock syndrome secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Toxic shock syndrome secondary prevention

CDC on Toxic shock syndrome secondary prevention

Toxic shock syndrome secondary prevention in the news

Blogs on Toxic shock syndrome secondary prevention

Directions to Hospitals Treating Toxic shock syndrome

Risk calculators and risk factors for Toxic shock syndrome secondary prevention

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

References

Chemoprophylaxis of household contacts of STSS patients: Household contacts of people with STSS have a higher risk of invasive GAS infection compared to the general population. The Centers for Disease Control and Prevention have not made definite recommendations; some authors have recommended a 10-day course of cephalosporin

The risk of secondary cases of invasive disease is low at 2.9 per 1000. [null [82]] Several regimens have been successful in eradicating group A streptococcus from the pharynx of chronic carriers (i.e., rifampin plus intramuscular benzathine penicillin or a 10-day course of a second-generation cephalosporin or clindamycin). [null [107]] However, there are limited data concerning chemoprophylaxis for severe invasive group A streptococcal or staphylococcal infections.

American Academy of Pediatrics. Severe invasive group A streptococcal infection: a subject review. Pediatrics. 1998;101:136-140

Tanz RR, Poncher JR, Corydon KE, et al. Clindamycin treatment of chronic pharyngeal carriage of group a streptococci. J Pediatr. 1991;119:123-128